Congenital Fibrinogen Disorders

ABSTRACT

Inherited disorders of fibrinogen affect either the quantity (afibrinogenemia and hypofibrinogenemia) or the quality (dysfibrinogenemia) of the circulating fibrinogen or both (hypodysfibrinogenemia). Most often, patients with congenital fibrinogen disorders suffer from a bleeding diathesis but paradoxically may undergo severe thrombotic episodes. Pregnancy loss is another common clinical complication. Even in specialized laboratories, the precise diagnosis of some fibrinogen disorders may be challenging. Characterization of the molecular defect(s) is important as it provides a more accurate diagnosis, may enable prenatal diagnosis, will help elaborate a diagnostic strategy, and may distinguish in some cases those patients at risk of thrombosis rather than bleeding. However, the phenotype-genotype correlation is not easy to establish, and global hemostasis assays may provide a better evaluation of the patient's hemostatic state. Replacement therapy is effective in treating bleeding episodes, but it is important to tailor individual treatments because the pharmacokinetics of fibrinogen after replacement therapy is highly variable among patients. Although the number of cases studied and identified mutations are already quite substantial, the collection and comparison of molecular, biochemical, and clinical data will continue to yield valuable information on the development and course of these diseases, as well as on the choice of the most appropriate treatments.

KEYWORDS

Bleeding disorder - fibrinogen - afibrinogenemia - dysfibrinogenemia - hypofibrinogenemia

REFERENCES

• 1 Haverkate F, Samama M. Familial dysfibrinogenemia and thrombophilia. Report on a study of the SSC Subcommittee on Fibrinogen.  Thromb Haemost. 1995;  73 151-161
• 2 Lak M, Keihani M, Elahi F, Peyvandi F, Mannucci P M. Bleeding and thrombosis in 55 patients with inherited afibrinogenaemia.  Br J Haematol. 1999;  107 204-206
• 3 Acharya S S, Coughlin A, Dimichele D M. North American Rare Bleeding Disorder Study Group . Rare Bleeding Disorder Registry: deficiencies of factors II, V, VII, X, XIII, fibrinogen and dysfibrinogenemias.  J Thromb Haemost. 2004;  2 248-256
• 4 Bolton-Maggs P HB, Perry D J, Chalmers E A et al.. The rare coagulation disorders—review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation.  Haemophilia. 2004;  10 593-628
• 5 Peyvandi F, Haertel S, Knaub S, Mannucci P M. Incidence of bleeding symptoms in 100 patients with inherited afibrinogenemia or hypofibrinogenemia.  J Thromb Haemost. 2006;  4 1634-1637
• 6 McDonagh J. Dysfibrinogenemia and other disorders of fibrinogen structure or function. In: Colman R, Hirsh J, Marder V, Clowes A, George J Hemostasis and Thrombosis. Basic Principles and Clinical Practice. Philadelphia, PA; Lippincott Williams & Wilkins 2001: 855-892
• 7 Maghzal G J, Brennan S O, Homer V M, George P M. The molecular mechanisms of congenital hypofibrinogenaemia.  Cell Mol Life Sci. 2004;  61 1427-1438
• 8 Neerman-Arbez M, de Moerloose P. Mutations in the fibrinogen gene cluster accounting for congenital afibrinogenemia: an update and report of 10 novel mutations.  Hum Mutat. 2007;  28 540-553
• 9 Mosesson M W, Siebenlist K R, Meh D A. The structure and biological features of fibrinogen and fibrin.  Ann N Y Acad Sci. 2001;  936 11-30
• 10 Kant J A, Fornace Jr A J, Saxe D, Simon M I, McBride O W, Crabtree G R. Evolution and organization of the fibrinogen locus on chromosome 4: gene duplication accompanied by transposition and inversion.  Proc Natl Acad Sci U S A. 1985;  82 2344-2348
• 11 Fuller G M, Zhang Z. Transcriptional control mechanism of fibrinogen gene expression.  Ann N Y Acad Sci. 2001;  936 469-479
• 12 Mosesson M W. Hereditary fibrinogen abnormalities. In: Lichtman MA, Beutler E, Kaushansky K, Kipps TJ, Seligsohn U, Prchal J Williams Hematology, 7th ed. New York, NY; McGraw-Hill 2005: 1909-1927
• 13 Rabe F, Salomon E. Ueber-faserstoffmangel im Blute bei einem Falle von Hämophilie.  Arch Intern Med. 1920;  95 2-14
• 14 Peyvandi F, Kaufman R J, Seligsohn U et al.. Rare bleeding disorders.  Haemophilia. 2006;  12(Suppl 3) 137-142
• 15 Ehmann W C, al-Mondhiry H. Congenital afibrinogenemia and splenic rupture.  Am J Med. 1994;  96 92-94
• 16 Suh T T, Holmbäck K, Jensen N J et al.. Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen-deficient mice.  Genes Dev. 1995;  9 2020-2033
• 17 Iwaki T, Sandoval-Cooper M J, Paiva M, Kobayashi T, Ploplis V A, Castellino F J. Fibrinogen stabilizes placental-maternal attachment during embryonic development in the mouse.  Am J Pathol. 2002;  160 1021-1034
• 18 Dupuy E, Soria C, Molho P et al.. Embolized ischemic lesions of toes in an afibrinogenemic patient: possible relevance to in vivo circulating thrombin.  Thromb Res. 2001;  102 211-219
• 19 Girolami A, Ruzzon E, Tezza F, Scandellari R, Vettore S, Girolami B. Arterial and venous thrombosis in rare congenital bleeding disorders: a critical review.  Haemophilia. 2006;  12 345-351
• 20 De Marco L, Girolami A, Zimmerman T S, Ruggeri Z M. von Willebrand factor interaction with the glycoprotein IIb/IIa complex. Its role in platelet function as demonstrated in patients with congenital afibrinogenemia.  J Clin Invest. 1986;  77 1272-1277
• 21 Korte W, Feldges A. Increased prothrombin activation in a patient with congenital afibrinogenemia is reversible by fibrinogen substitution.  Clin Investig. 1994;  72 396-398
• 22 de Bosch N B, Mosesson M W, Ruiz-Sáez A, Echenagucia M, Rodriguez-Lemoin A. Inhibition of thrombin generation in plasma by fibrin formation (antithrombin I).  Thromb Haemost. 2002;  88 253-258
• 23 Mosesson M W, Antithrombin I. Antithrombin I. Inhibition of thrombin generation in plasma by fibrin formation.  Thromb Haemost. 2003;  89 9-12
• 24 Ni H, Denis C V, Subbarao S et al.. Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen.  J Clin Invest. 2000;  106 385-392
• 25 Remijn J A, Wu Y-P, Ijsseldijk M J, Zwaginga J J, Sixma J J, de Groot P G. Absence of fibrinogen in afibrinogenemia results in large but loosely packed thrombi under flow conditions.  Thromb Haemost. 2001;  85 736-742
• 26 Henselmans J M, Meijer K, Haaxma R, Hew J, van der Meer J. Recurrent spontaneous intracerebral hemorrhage in a congenitally afibrinogenemic patient: diagnostic pitfalls and therapeutic options.  Stroke. 1999;  30 2479-2482
• 27 Brennan S O, Wyatt J, Medicina D, Callea F, George P M. Fibrinogen brescia: hepatic endoplasmic reticulum storage and hypofibrinogenemia because of a gamma284 Gly—> Arg mutation.  Am J Pathol. 2000;  157 189-196
• 28 Brennan S O, Maghzal G, Shneider B L, Gordon R, Magid M S, George P M. Novel fibrinogen gamma375 Arg—> Trp mutation (fibrinogen aguadilla) causes hepatic endoplasmic reticulum storage and hypofibrinogenemia.  Hepatology. 2002;  36 652-658
• 29 Dib N, Quelin F, Ternisien C et al.. Fibrinogen angers with a new deletion (gamma GVYYQ 346-350) causes hypofibrinogenemia with hepatic storage.  J Thromb Haemost. 2007;  5 1999-2005
• 30 Hayes T. Dysfibrinogenemia and thrombosis.  Arch Pathol Lab Med. 2002;  126 1387-1390
• 31 Colvin R B, Mosesson M W, Dvorak H F. Delayed-type hypersensitivity skin reactions in congenital afibrinogenemia lack fibrin deposition and induration.  J Clin Invest. 1979;  63 1302-1306
• 32 Roberts H R, Stinchcombe T E, Gabriel D A. The dysfibrinogenaemias.  Br J Haematol. 2001;  114 249-257
• 33 Neerman-Arbez M, Honsberger A, Antonarakis S E, Morris M A. Deletion of the fibrinogen alpha-chain gene (FGA) causes congenital afibrinogenemia.  J Clin Invest. 1999;  103 215-218
• 34 Vu D, Neerman-Arbez M. Molecular mechanisms accounting for fibrinogen deficiency: from large deletions to intracellular retention of misfolded proteins.  J Thromb Haemost. 2007;  5(Suppl 1) 125-131
• 35 Platè M, Asselta R, Peyvandi F, Tenchini M L, Duga S. Molecular characterization of the first missense mutation in the fibrinogen Aalpha-chain gene identified in a compound heterozygous afibrinogenemic patient.  Biochim Biophys Acta. 2007;  1772 781-787
• 36 Platè M, Asselta R, Spena S et al.. Congenital hypofibrinogenemia: characterization of two missense mutations affecting fibrinogen assembly and secretion.  Blood Cells Mol Dis. 2008;  41 292-297
• 37 Galanakis D K, Neerman-Arbez M, Scheiner T et al.. Homophenotypic Aalpha R16H fibrinogen (Kingsport): uniquely altered polymerization associated with slower fibrinopeptide A than fibrinopeptide B release.  Blood Coagul Fibrinolysis. 2007;  18 731-737
• 38 Hanss M, Biot F. A database for human fibrinogen variants.  Ann N Y Acad Sci. 2001;  936 89-90
• 39 Ingerslev J, Sørensen B, Castaman G, Lloyd J V, Varon J D, Savion N. New approaches in the measurement of coagulation.  Haemophilia. 2008;  14(Suppl 3) 104-112
• 40 Neerman-Arbez M, Vu D, Abu-Libdeh B, Bouchardy I, Morris M A. Prenatal diagnosis for congenital afibrinogenemia caused by a novel nonsense mutation in the FGB gene in a Palestinian family.  Blood. 2003;  101 3492-3494
• 41 Santagostino E, Mancuso M E, Morfini M et al.. Solvent/detergent plasma for prevention of bleeding in recessively inherited coagulation disorders: dosing, pharmacokinetics and clinical efficacy.  Haematologica. 2006;  91 634-639
• 42 de Moerloose P, Neerman-Arbez M. Treatment of congenital fibrinogen disorders.  Expert Opin Biol Ther. 2008;  8 979-992
• 43 Santacroce R, Cappucci F, Pisanelli D et al.. Inherited abnormalities of fibrinogen: 10-year clinical experience of an Italian group.  Blood Coagul Fibrinolysis. 2006;  17 235-240
• 44 De Vries A, Rosenberg T, Kochwa S, Boss J H. Precipitating antifibrinogen antibody appearing after fibrinogen infusions in a patient with congenital afibrinogenemia.  Am J Med. 1961;  30 486-494
• 45 Ra'anani P, Levi Y, Varon D, Gitel S, Martinowitz U. [Congenital afibrinogenemia with bleeding, bone cysts and antibodies to fibrinogen].  Harefuah. 1991;  121 291-293
• 46 Schuepbach R A, Meili E O, Schneider E, Peter U, Bachli E B. Lepirudin therapy for thrombotic complications in congenital afibrinogenaemia.  Thromb Haemost. 2004;  91 1044-1046
• 47 Négrier C, Rothschild C, Goudemand J et al.. Pharmacokinetics and pharmacodynamics of a new highly secured fibrinogen concentrate.  J Thromb Haemost. 2008;  6 1494-1499
• 48 Galanakis D K. Fibrinogen anomalies and disease. A clinical update.  Hematol Oncol Clin North Am. 1992;  6 1171-1187
• 49 Vakalopoulou S, Rizopoulou D, Zafiriadou E et al.. Management of acute bleeding in a patient with congenital afibrinogenaemia.  Haemophilia. 2006;  12 676-678
• 50 Kreuz W, Meili E, Peter-Salonen K et al.. Pharmacokinetic properties of a pasteurised fibrinogen concentrate.  Transfus Apher Sci. 2005b;  32 239-246
• 51 Bishop P, Lawson J. Recombinant biologics for treatment of bleeding disorders.  Nat Rev Drug Discov. 2004;  3 684-694
• 52 Tojo N, Miyagi I, Miura M, Ohi H. Recombinant human fibrinogen expressed in the yeast Pichia pastoris was assembled and biologically active.  Protein Expr Purif. 2008;  59 289-296
• 53 Grech H, Majumdar G, Lawrie A S, Savidge G F. Pregnancy in congenital afibrinogenaemia: report of a successful case and review of the literature.  Br J Haematol. 1991;  78 571-572
• 54 Kobayashi T, Kanayama N, Tokunaga N, Asahina T, Terao T. Prenatal and peripartum management of congenital afibrinogenaemia.  Br J Haematol. 2000;  109 364-366